I beg to difer on your assessment of the Abbott licensing deal. Dr. Moro agreed to the small upfront in order to receive a much higher percentage of the revenue once the recaf based test begins to sell! The upfront money had nothing to do with Abbott not getting exclusive rights. Abbott agreed to the much higher percentage because of Biocurex's show of faith in their technology, accepting only 200K, upfront. Also, Abbott was amazed at the potential this technology demonstrated during it's due dilligence phase. If and when the details of the agreement become public, or deciphered through the eventual quarterly reports, you'll see what I mean!
Now, one of Biocurex's intentions for granting non-exclusive rights, as opposed to exclusive rights to Abbott, is to set a fire, ensuring that Abbott will not become complacent with this technology, creating a competitive atmosphere in getting this thing to market! It will work out to be advantageous for all of those that are long on this stock!Biocurex understands that in the long run, due to demand and sales, this arrangement will be substantially more profitable.
